Xelox clinical trials
How each study uses xelox is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the xelox studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
60 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 52
Harbin Medical University (4) · Fudan University (3) · West China Hospital (2) · Peking University Cancer Hospital & Institute (2) · AstraZeneca (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Henan Cancer Hospital (2) · Tang-Du Hospital (2)
Often tested with
Tested in the same studies.
CAPOX Regimen (17) · Sintilimab (7) · Bevacizumab (6) · Folfox protocol (4) · XELIRI Regimen (4) · Modified FOLFOX Regimen (3) · Oxaliplatin (3) · FOLFOXIRI Regimen (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Xelox is the comparator. A study of two new drugs counts under both.
- 1Balstilimab · Centre Leon Berard · next primary completion May 2028
- 1Botensilimab · Centre Leon Berard · next primary completion May 2028
- 1Dostarlimab · GlaxoSmithKline · next primary completion Mar 2029
- 1Iparomlimab/Tuvonralimab · Qilu Pharmaceutical Co., Ltd. · next primary completion Dec 2030
- 1Fluorouracil · Chinese University of Hong Kong
- 1Leucovorin · Chinese University of Hong Kong
- 1Oxaliplatin · Chinese University of Hong Kong
- 1Docetaxel · Chinese University of Hong Kong
Reaching primary completion within a year · 10
Studies that test xelox.
- Dec 2026A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersPhase 2 · Shenyang Sunshine Pharmaceutical Co., LTD.
- Dec 2026Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisPhase 2 · Peking University Cancer Hospital & Institute
- Dec 2026XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJCPhase 1/2 · West China Hospital
- Jan 2027AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ CancerPhase 2 · Harbin Medical University
- Feb 2027A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E MutationPhase 2 · Yanqiao Zhang
- Feb 2027SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.Phase 2 · The First Affiliated Hospital with Nanjing Medical University
- Feb 2027FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver MetastasisPhase 2 · Hua Jiang
- May 2027Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal CancerPhase 2 · Zhen-Hai Lu
- Sep 2027Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerPhase 2 · Sun Yat-sen University
- Nov 2027Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPhase 2 · AstraZeneca
Studies
Open first, then newest update. How each study uses xelox is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 60
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07448142Written as CAPEOX/XELOX
- FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver MetastasisRecruitingPhase 2Hua JiangNCT06801665Written as FMT+QL1706+Bevacizumab+XELOX
- A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07622550Written as Serplulimab+Fruquintinib+XELOX
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AstraZenecaNCT05702229Written as XELOX
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaRecruitingPhase 2Fudan UniversityNCT07328009Written as XELOX + QL1706+TKI
- LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver MetastasisRecruitingPhase 1Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT06848465Written as XELOX
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07503639Written as XELOX (Capecitabine and Oxaliplatin)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With OligometastasesRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06850103Written as CAPEOX/XELOX
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E MutationNot yet recruitingPhase 2Yanqiao ZhangNCT07229846Written as XELOX + Bevacizumab
- A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersNot yet recruitingPhase 2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07233850Written as SSGJ-706+Bevacizumab+XELOX
- SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerRecruitingPhase 2Ruijin HospitalNCT05576480Written as CAPEOX
- Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ CancerRecruitingPhase 1/2Henan Cancer HospitalNCT06329973Written as Fruquintinib in combination with Sintilimab and CAPEOX
- Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07007728Written as Bevacizumab + CAPEOX
- XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJCRecruitingPhase 1/2West China HospitalNCT06742411Written as XELOX+Sintilimab+HBOT
- Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal CancerRecruitingPhase 2fan liNCT06718543Written as AK112 with SCRT and CapeOX
- Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid TumorsRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT06621563Written as HS-20117+CAPEOX
- BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.RecruitingPhase 1Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.NCT06773312Written as BC001+Sintilimab+XELOX
- SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.Not yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06835179Written as CapeOX + bevacizumab
- To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal CancerRecruitingPhase 2xiaohua liNCT06808412Written as sintilimab combined with bevacizumab and XELOX
- HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon CancerRecruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT06709885Written as Chidamide + Tislelizumab + chemotherapy (CapeOX )
See all 60 studies that test xelox →
Given beside what is tested · 31 — xelox is usual care or a partner of the new treatment
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNot applicableTang-Du HospitalNCT06128252Written as XELOX regimen
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerRecruitingPhase 2GlaxoSmithKlineNCT06567782Written as CAPEOX
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsNot yet recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT07381777Written as XELOX (Capecitabine and Oxaliplatin)
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma:A Randomized, Non-comparative Phase 2 StudyNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07266025Written as XELOX
- QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon CancerNot yet recruitingPhase 2Qilu Hospital of Shandong UniversityNCT07156682Written as XELOX
- Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral NeuropathyNot yet recruitingPhase 2Shandong New Time Pharmaceutical Co., LTDNCT06722950Written as CAPEOX
- Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ PatientsRecruitingPhase 1/2Zhejiang Cancer HospitalNCT06650332Written as XELOX
- A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver MetastasisNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06564298Written as SOX/XELOX
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCRecruitingPhase 2Peking UniversityNCT06023758Written as XELOX
- Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.Not yet recruitingPhase 2Xiangdong ChengNCT06374901Written as SOX/XELOX
- Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT06014372Written as CAPEOX
- Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric CancerRecruitingPhase 2Tang-Du HospitalNCT06123455Written as XELOX regimen
- XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05494060Written as XELOX
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT05985707Written as XELOX
- The Value of Palliative Primary Tumor Resection in Metastatic Colon CancerRecruitingPhase 3Fudan UniversityNCT04416854Written as XELOX
- Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term RadiationRecruitingPhase 3Sun Yat-sen UniversityNCT03671252Written as XELOX
- XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring CarcinomaNot yet recruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT03355612Written as XELOX
- Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal CancerActive, not recruitingPhase 3Shandong Cancer Hospital and InstituteNCT06246344Written as CAPEOX
- Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedPhase 1/2National Cancer Center Hospital EastNCT05394740Written as CapeOX
- Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal TumorsCompletedPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT05515796Written as CapeOx
Showing 20 of 31.
As the comparator · 14 — what is tested is compared with xelox
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197Written as XELOX
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerRecruitingPhase 3GlaxoSmithKlineNCT05855200Written as CAPEOX
- A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon CancerRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06686576Written as CAPEOX/Capecitabine
- CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)RecruitingPhase 2West China HospitalNCT06242418Written as XELOX
- Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT06443671Written as CapeOX
- Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric CancerRecruitingPhase 2Lin ChenNCT06284746Written as SOX/XELOX
- Perioperative FLOT vs Adjuvant XELOX for CA StomachRecruitingPhase 3Chinese University of Hong KongNCT05264896Written as XELOX
- PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical SurgeryActive, not recruitingPhase 2Fudan UniversityNCT05468138Written as XELOX
- Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction CancersStatus unknownPhase 3Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT02934464Written as XELOX
- Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant ChemotherapyStatus unknownPhase 2Peking Union Medical College HospitalNCT03322969Written as XELOX/SOX
- SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal CancerStatus unknownPhase 2The First People's Hospital of ChangzhouNCT02870153Written as XELOX
- Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer PatientsStatus unknownPhase 2Tianjin Medical University Cancer Institute and HospitalNCT01618474Written as XELOX
- Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal CancerCompletedPhase 2Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)NCT01071655Written as BVZ+XELOX
- Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal CancerCompletedPhase 2Hallym University Medical CenterNCT00677144Written as XELOX (oxalipaltin+capecitabine)